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The Hippo pathway defined originally in Drosophila melanogaster is conserved in mammals. The fly core 
components Hippo, Sav, Wts, and Mats are conserved in mammals as Mst1/2, WW45, LATS1/2, and 
Mob1. The pathway impinges on transcriptional coactivator Yorkie in fly and YAP in mammals to coordi-
nate cell proliferation and apoptosis. Several recent publications establish that the pathway is one major 
conserved mechanism governing cell contact inhibition, organ size control, and cancer development. This 
advance opens new vistas in exploring fundamental mechanisms in cell and developmental biology and 
offers potential targets to interfere with cancer development.During normal development, each organ is patterned not only 
to a specific architecture but also to a defined final size (Har-
vey and Tapon, 2007; Pan, 2007; Saucedo and Edgar, 2007). 
Organ size control is also evident during regeneration after 
tissue injury or experimental procedures. For example, after 
partial hepatectomy, the hepatocytes in the liver are mobilized 
to divide rapidly to increase the size of the regenerating liver. 
Upon reaching the original size, the cells cease dividing to 
ensure that the regenerating liver is not over-grown (Fausto et 
al., 2006).
At the cellular level, epithelial cells in vivo and cultured in 
vitro exhibit contact inhibition arising from cell-cell and cell-
substrata interactions (with basement membrane in vivo and 
cultureware in vitro) (Eagle and Levine, 1967). Contact inhibi-
tion ensures that epithelial cells will stop proliferation once 
they have reached confluence. Most human cancer cells 
are refractory to contact inhibition. As a consequence, they 
are able to continue proliferation in spite of interactions with neighboring cells and substrata. In more aggressive stages, 
the dividing cancer cells can invade the surrounding tissue 
to achieve unlimited growth and can eventually metastasize 
to secondary sites. Many established cancer cell lines also 
exhibit growth in vitro that is impervious to contact inhibi-
tion, and often display anchorage-independent growth in soft 
agar. The loss of contact inhibition and the gain of anchor-
age-independent growth are hallmarks of cancer cells in vitro 
(Hanahan and Weinberg, 2000), suggesting that many onco-
genic alterations either uncouple cell proliferation from the 
mechanism that subjects it to contact inhibition, or alter the 
contact inhibition mechanism itself.
The Hippo pathway was initially identified in the fly to control 
organ size, and its core components are evolutionally conserved 
in mammals. The discoveries made in the fly have provided 
the paradigm for follow-on studies of mammalian components 
(Harvey and Tapon, 2007; Pan, 2007; Saucedo and Edgar, 
2007). Several recent studies have clearly established a role for 188 Cancer Cell 13, March 2008 ©2008 Elsevier Inc.
Table 1. Summary of the Core Components of the Hippo Pathway and the Downstream Target YAP in Drosophila melano-
gaster and in Human
Drosophila Accession No. Size (aa) Human Accession No. Size (aa)
Hippo Q8T0S6, AAF57543 669 Mst1/STK4 NP_006273 487
Mst2/STK3 NP_006272 491
Salvador Q9VCR6 608 WW45/Sav1 NP_068590 383
Warts/LATS AAA70336, AAA73959 1099 LATS1 NP_004681 1130
LATS2 NP_055387 1088
Mats Q95RA8 219 Mob1 NP_060691 216
Yorkie AAZ42161, 
NP_001036568
418 YAP NP_006097 454
TAZ/WWTR1 NP_056287 400
The name, accession number (at http://www.ncbi.nlm.nih.gov/), and length (number of amino acid [aa] residues) of each 
protein are indicated. Mammalian TAZ/WWTR1 is a candidate target of the Hippo pathway.
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size control, and cancer development in mammals (Camargo 
et al., 2007; Dong et al., 2007; Zhao et al., 2007).
Core Machinery of the Hippo Pathway
Genetic screens in the 90s on Drosophila melanogaster for 
mutants exhibiting tissue overgrowth identified Warts (Wts) as 
the first component of the Hippo pathway (Justice et al., 1995; 
Xu et al., 1995). Yet, only in 2002 was the second component 
of the pathway, Salvador (Sav), identified. Functional loss of 
Sav results in overexpression of the cell-cycle regulator cyclin 
E and the antiapoptotic dIAP1 (Tapon et al., 2002). Subsequent 
studies uncovered the Hippo (Hpo) component and placed 
Hippo upstream of Wts (Harvey et al., 2003; Pantalacci et al., 
2003; Udan et al., 2003; Wu et al., 2003) and established that 
Sav potentiates the activity of Hippo (Wu et al., 2003). Mats 
was identified 3 years ago as the fourth component that inter-
acts with and enhances the activity of Wts (Lai et al., 2005). 
Hippo, Sav, Wts, and Mats are core components of the fly 
Hippo pathway and are homologous to mammalian Mst1/2, 
WW45, LATS1/2, and Mob1, respectively (Table 1). Functional 
conservation is evident, since LATS1, Mst2, and Mob1 can 
rescue corresponding fly mutants in vivo (Harvey and Tapon, 
2007; Pan, 2007; Saucedo and Edgar, 2007).
Hippo, Mst1, and Mst2 belong to the STE20 (Sterile20) fam-
ily of protein kinases. Their N-terminal region contains a Ser/
Thr protein kinase domain (Figure 1), while coiled-coil domains 
are predicted in the central and C-terminal regions. The C-ter-
minal coiled-coil region has been referred to as the SARAH 
(Sav/Rassf/Hpo) domain (Scheel and Hofmann, 2003). Sav and 
WW45 contain two WW domains, and the C-terminal region 
contains a SARAH domain (Figure 1). Type I WW domains 
are known to recognize PPXY motifs. The C-terminal SARAH 
domain of Mst1/2 interacts with the corresponding SARAH 
domain of WW45 (Callus et al., 2006). Wts, LATS1, and LATS2 
belong to the NDR (Nuclear Dbf-2-related) protein kinase family 
with the Ser/Thr protein kinase domain in the C-terminal region 
(Figure 1). Further downstream of the kinase domain is the S_
TK_X region, while the N-terminal region contains a UBA (ubiq-
uitin-associated) motif that is implicated in ubiquitin-mediated 
processes. Several PPXY motifs are present in both Wts and 
LATS1/2 and are expected to interact with WW domain proteins. 
Knockout of the LATS1 gene in mice causes ovarian tumors 
and soft-tissue sarcoma (St John et al., 1999), while LATS2-
deficient mouse embryonic fibroblasts overcome contact inhibi-
tion (McPherson et al., 2004). Mats and Mob1 are small proteins 
consisting essentially of a Mob1 domain implicated in protein-
protein interaction (Figure 1). The four Hippo core components 
form two protein kinase complexes (each with a regulatory sub-
unit) acting in a cascade such that Hippo/Mst1/2 interacts with 
Sav/WW45 to phosphorylate and activate the complex formed 
by Wts/LATS1/2 and Mats/Mob1 (Harvey and Tapon, 2007; Pan, 
2007; Saucedo and Edgar, 2007) (Figure 2).
Yorkie as the Major Target of the Hippo Pathway
Given that Wts/LATS1/2-Mats/Mob1 is a protein kinase com-
plex, its downstream substrates would define the mechanics 
of the Hippo pathway. To this end, protein interaction screens using Wts identified the transcriptional coactivator Yorkie as a 
major downstream target of the Wts-Mats complex in the fly 
(Huang et al., 2005). Mechanistically, Yorkie is phosphorylated 
and inactivated by Wts, whereas overexpression of Yorkie 
yields a tissue overgrowth phenotype similar to Wts mutation. 
Conversely, inactivation of Yorkie through mutations leads to 
tissue atrophy. Thus, the Hippo core components can nega-
tively regulate Yorkie through direct phosphorylation (Figure 
2). Analogous to overexpression of Yorkie itself, mutations of 
the Hippo core components are thus expected to increase the 
activity of Yorkie, resulting in enhanced transcription of its tar-
get genes such as cyclin E and dIAP1 that promote cell prolif-
eration and/or suppress cell death.
YAP is the mammalian homolog of Yorkie and can function-
ally rescue Yorkie mutation in the fly, which suggests that YAP 
is a functional counterpart of Yorkie and is likely to promote 
proliferation. However YAP may also exhibit proapoptotic activ-
ity under certain conditions, such as DNA damage (Matallanas 
et al., 2007). YAP contains a WW domain for interaction with 
PPXY motifs, a predicted coiled-coil region, and a C-terminal 
TWL motif for interaction with PDZ domains (Figure 1), while its 
N-terminal region is rich in Pro.
Recent studies support that YAP is an oncogene in mam-
malian cells (Overholtzer et al., 2006; Zender et al., 2006). First, 
genome-wide analysis of mouse liver tumors revealed recur-
rent chromosome amplification at 9qA1, syntenic to human 
chromosome region 11q22. Amplification of 11q22 has been 
observed in several human cancers. Two candidate oncogenes 
Figure 1. Schematic Illustration of Domain Organization and Key 
Structural Features of Human Hippo Core Components and YAP
Mst1 and LATS2, structurally similar to Mst2 and LATS1, respectively, are not 
shown. The indicated domains are S_TKc for catalytic Ser/Thr protein kinase, 
CC for coiled coil, Sarah for Sav/Rassf/Hpo domain, WW for domain with two 
conserved Trp (W) residues, UBA for ubiquitin associated domain, S_TK_X 
for extension to Ser/Thr-type protein kinases, Mob1 for Mob1/phocein, and 
P-rich for Pro-rich. The two PPXP motifs in LATS1 are indicated. The HXRXXS 
motif with S127 targeted by LATS1 and the C-terminal PZD-binding motif of 
YAP are also indicated. The interaction of Mst2 with WW45 (mediated by the 
C-terminal Sarah domains) and the interaction of LATS1 and Mob1 are in-
dicated by double-arrow-ended solid red lines, while the potential interac-
tions of the PPXY motifs on LATS1 with the WW domain of WW45 and YAP 
are indicated by double-arrow-ended dotted red lines. The link between the 
catalytic domain of LATS1 and S127 phosphorylation site of YAP is indicated 
by an arrowed blue line. The general organization and the corresponding S89-
containing HXRXXS motif of TAZ/WWTR1 are also included, as TAZ is a can-
didate target of the Hippo pathway.Cancer Cell 13, March 2008 ©2008 Elsevier Inc. 189
Cancer Cell
Minireviewin the amplified region are YAP and cIAP1, the latter being a dIAP1-
related protein. YAP and cIAP1 are individually oncogenic, but 
they can cooperate to yield accelerated tumor growth (Zender et 
al., 2006). In a separate screen, an amplification of a smaller chro-
mosomal region within 9qA1 was identified in mouse mammary 
tumors, and YAP is the only gene within this narrower region. Over-
expression of YAP in nontransformed human MCF10A mammary 
epithelial cells causes epithelial-mesenchymal transition, sup-
pression of apoptosis, growth factor-independent proliferation, 
and anchorage-independent growth in soft agar (Overholtzer et 
al., 2006). Consistent with the proproliferating and antiapoptotic 
functions of YAP, knockout of the YAP gene in mice leads to early 
embryonic lethality (Morin-Kensicki et al., 2006).
A Conserved Mechanism Governing Cell Contact 
Inhibition, Organ Size Control, and Cancer Development 
from Fly to Mammals
Three recent reports have elucidated the molecular mecha-
nism through which Yorkie/YAP is regulated by the Hippo path-
way to govern cell contact inhibition, organ size control, and 
Figure 2. Schematic Illustration of the Signaling Cascade of the 
Hippo Pathway
Hippo/Mst, Sav/WW45, Wts/Lats, and Mats/Mob1 are the core components 
of the Hippo pathway. Upstream signals transmitted from proteins such as 
Fat, Mer, and Ex in the fly (or NF2 and other yet to be established human 
counterparts) upon reaching cell confluence and/or defined organ size cause 
activation of the Hippo/Mst-Sav/WW45 complex via an unknown mechanism, 
although protein phosphorylation of Hippo/Mst is a likely possibility. In addi-
tion to regulating Ex, Fat may act in parallel to Ex/Hippo to directly activate 
LATS through relieving its inhibition by the atypical myosin Dachs. Wts/Lats-
Mats/Mob1 is activated by Hippo/Mst-mediated phosphorylation. Yorkie/YAP 
is normally translocated into the nucleus, where it acts as a transcriptional 
coactivator to coordinate proproliferating and antiapoptotic programs and 
is phosphorylated (primarily at S168/S127) by the activated Wts/Lats-Mats/
Mob1 complex, causing cytoplasmic sequestration of phosphorylated Yorkie/
YAP via interactions with 14-3-3 proteins. Cytoplasmic sequestration of York-
ie/YAP suppresses the proproliferating and antiapoptotic program, leading to 
the arrest of cell proliferation and organ growth. Mutations of the Hippo core 
components or overexpression of Yorkie/YAP increase the levels of functional 
Yorkie/YAP in the nucleus to sustain the proliferating and antiapoptotic tran-
scriptional programs and overcome normal contact inhibition and organ size 
control to promote cancer development. TAZ/WWTR1 is a candidate down-
stream target of the Hippo pathway in mammalian cells and is likely to be 
regulated similar to YAP.190 Cancer Cell 13, March 2008 ©2008 Elsevier Inc.cancer development (Camargo et al., 2007; Dong et al., 2007; 
Zhao et al., 2007). Guan’s laboratory noted that the subcellular 
location of YAP is dependent on cell density. YAP is primar-
ily present within the nucleus in sparsely growing cells, where 
it functions as a transcriptional coactivator. Upon confluence, 
when contact inhibition comes into play, YAP accumulates in 
the cytoplasm, thereby rendering it unable to function as a 
transcriptional coactivator. This cytoplasmic sequestration of 
YAP in response to cell density correlates with its increased 
phosphorylation. Mst2 and LATS2 act coordinately to phos-
phorylate YAP at HXRXXS motifs, with the S127-containing 
motif being the major site. Yorkie has a corresponding motif 
with S168 as the major site targeted by Wts. In sparsely cul-
tured cells, overexpression of LATS2 leads to S127 phospho-
rylation of YAP and its cytoplasmic sequestration, but mutation 
of the S127 into Ala abrogates this cytoplasmic shift. Circum-
venting the regulation of YAP and Yorkie by LATS2 and Wts 
through the S127A/S168A mutation also results in enhanced 
growth-promoting activity. The cytoplasmic sequestration of 
S127-phosphoryalted YAP results from its enhanced interac-
tions with 14-3-3 proteins (Zhao et al., 2007), which are known 
to sequester phosphorylated YAP in the cytosol (Basu et al., 
2003). This study suggests that when cultured cells reach con-
fluence, cell-cell interactions trigger a cascade of signaling 
events that activate the Hippo pathway. The activated LATS-
Mob1 complex phosphorylates YAP (preferentially at S127), 
leading to enhanced interactions with 14-3-3 proteins and 
cytoplasmic sequestration. This results in reduced transcrip-
tion of YAP target genes, manifesting a growth cessation that 
is referred to as cell contact inhibition.
Working with Drosophila, Pan’s laboratory showed that the 
Hippo pathway leads to cytoplasmic sequestration of Yorkie 
and that S168 in the HXRXXS motif is the principle site phos-
phorylated by Wts. Wts-mediated phosphorylation of Yorkie 
S168 is the mechanistic basis for cell growth suppression by 
the Hippo pathway. In addition, loss of Hippo signaling due to 
mutation of Hippo or Wts results in nuclear accumulation of 
Yorkie, reflecting the role of the Hippo pathway in phosphory-
lating S168 of Yorkie to mediate its cytoplasmic sequestration. 
Pan’s team also established the biochemical and functional 
conservation of the Hippo pathway in mammals, its growth-
suppressing effects, and the S127 phosphorylation of YAP by 
LATS1/2 as the substantive mechanism. More significant was 
the demonstration that variations of YAP levels can overcome 
organ size control; a regulated increase of YAP expression 
in the liver of transgenic mice led to a striking enlargement 
of the liver due largely to increased cell numbers. Sustained 
overexpression of YAP can expand liver mass from 5% of 
bodyweight to about 25%, yet this effect is reversible, as the 
enlarged liver reverts to almost normal size when overexpres-
sion of YAP is restrained for a sufficient period of time. This 
dramatic and reversible manipulation of liver size through YAP 
changes alone positions the YAP-regulating Hippo pathway 
as the major mechanism controlling organ size in mammals. 
Presumably, when an organ reaches its programmed size, the 
Hippo pathway is triggered to inactivate YAP through phos-
phorylation and sequestration in the cytoplasm via interac-
tions with 14-3-3 proteins. Many growth-promoting or anti-
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c-Myc, Sox4, H19, AFP, BIRC5/survivin, and BIRC2/cIAP1. 
Indeed, the enhanced expression of BITC5/survivin is nec-
essary for YAP to induce anchorage-independent growth. 
Also, the upregulation of cIAP1 levels by YAP would effec-
tively coordinate cell proliferation by YAP and the suppres-
sion of apoptosis by cIAP1 and would explain the coampli-
fication of BIRC2/cIAP1 and YAP genes observed in mouse 
and human hepatocellular carcinoma. Finally, sustained high-
level expression of YAP in the liver of transgenic mice leads 
eventually to tumorigenesis characteristic of hepatocellular 
carcinoma (Dong et al., 2007).
A third study from Brummelkamp’s laboratory independently 
demonstrated that YAP is sufficient for inducible and reversible 
liver enlargement in transgenic mice. Significantly, this study 
also linked YAP expression to stem/progenitor cells in the 
intestine, since YAP is primarily expressed in the crypt com-
partment where these cells reside. Regulated YAP overexpres-
sion in the intestine of transgenic mice correlates with elevated 
levels of cyclin D and BclXL and causes dysplasia due to pro-
liferation of the crypt stem/progenitor cells. Interestingly, this 
parallels the correlation between YAP expression levels and 
enhanced levels of cyclin D and BclXL in human colon cancers. 
This study thus implicates YAP as a critical link between stem/
progenitor cells and colon cancer cells (Camargo et al., 2007). 
Collectively, these three studies suggest that overexpression 
of YAP or its overactivation due to intrinsic Hippo pathway 
mutations is able to abrogate cell contact inhibition and organ 
size control to promote cancer development.
Future Challenges
Despite this major advance in our understanding of the Hippo 
pathway, many questions remain to be answered. For example, 
how does the cell-cell interaction contingent upon confluence 
or the acquisition of normal organ size activate the Hippo path-
way? Although surface proteins such as Fat and submembrane 
scaffold proteins such as Merlin and Expanded (Ex) are known 
to be functionally associated with the Hippo pathway (Bennett 
and Harvey, 2006; Cho et al., 2006; Harvey and Tapon, 2007; 
Pan, 2007; Saucedo and Edgar, 2007; Silva et al., 2006; Wil-
lecke et al., 2006), the precise mechanism of these linkages 
with the Hippo core components has not been established. In 
addition to regulating Ex, Fat may act on an atypical myosin 
Dachs to prevent it inhibiting Wts so that Wts can be activated 
without engaging Hippo (Figure 2) (Cho et al., 2006; Feng and 
Irvine, 2007). While the mammalian homolog of Merlin is clearly 
the tumor suppressor neurofibromin 2 (NF2) (Hamaratoglu et 
al., 2006), the definitive mammalian Fat (speculated to be FatJ/
Fat4) and Ex (speculated to be FRMD6) remain uncertain, as 
there are many mammalian proteins that are homologous to 
Fat or Ex. Although Merlin and Ex are likely to transmit signals 
from surface proteins to the Hippo core machinery (Hamarato-
glu et al., 2006), we know little about the molecular detail.
The biochemical mechanism for activating the Mst1/-
-WW45 complex has yet to be defined, although the regulated 
phosphorylation of Hippo/Mst1/2 is a prime candidate. If that 
is indeed the case, then identification of the regulatory kinases 
and phosphatases will be key to understanding the integration of signals via the Hippo pathway. Although the sites on Wts/
LATS1/2 phosphorylated by Hippo/Mst1/2 have been defined 
(Chan et al., 2005) and Hippo also phosphorylates Mats (Wei et 
al., 2007), we know little about the phosphatases that dephos-
phorylate Wts/LATS and/or Yorkie/YAP. Since these phos-
phatases are likely to enhance the level of unphosphorylated 
Yorkie/YAP, leading to its nuclear accumulation, they will likely 
be growth-promoting. The systematic examination of all known 
phosphatases is one approach to identify them.
The mechanism of nuclear accumulation of Yorkie/YAP has not 
been explored. Also not established are the partner(s) of nuclear 
YAP in executing the proproliferating and antiapoptotic transcrip-
tional program. The Bantam microRNA is a downstream target of 
Yorkie in the fly (Nolo et al., 2006; Thompson and Cohen, 2006) 
and it will be interesting to examine whether YAP also regulates 
similar microRNA species in mammalian cells.
In addition to its major target, YAP, the Hippo core machin-
ery may target other substrates yet to be identified. Mamma-
lian TAZ is homologous to YAP and Yorkie and contains several 
HXRXXS motifs with S89 corresponding to S127 of YAP (Kanai 
et al., 2000). A recent report established that TAZ is indeed a 
substrate of the Hippo pathway in human cells (Lei et al., 2008). 
It would be interesting to explore polymorphisms of Hippo core 
components and/or YAP as a potential basis for the differing 
size and height of individuals.
Finally, unraveling the interconnections between the Hippo 
pathway and other signaling cascades that coordinate the cel-
lular programs in cell growth, proliferation, and apoptosis will be 
important. A known tumor suppressor, RASSF1, has recently been 
shown to regulate the Hippo pathway via interaction with Hippo/
Mst1/2 (Guo et al., 2007; Matallanas et al., 2007). It is tempting to 
speculate that RASSF1 functions as the entry point for Ras and 
other signaling pathways to modulate the Hippo pathway. Mst1/2 
has recently been shown to connect with the Akt kinase pathway 
(Cinar et al., 2007; Jang et al., 2007). With recent advances estab-
lishing the foundation, and exploiting the sophisticated genetic, 
genomic, and proteomics technologies at hand, we can expect 
rapid progress in addressing these questions. These answers will 
facilitate the development of assays to screen for molecules that 
interfere with the functionality of the Hippo pathway and YAP as 
candidates for anticancer drugs. Cellular components or small 
chemical compounds that are able to regulate YAP activity in a 
reversible manner offer potential handles to transiently regulate 
the organ size or even the size of an organism itself.
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